Please assess the completion status of the following clinical trial:

Trial Title: Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants 18 years and older.~* Known or suspected focal liver lesions based on medical history and previous laboratory and/or imaging examinations.~* Severe renal impairment (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m\^2) based on medical history and previous laboratory examinations, at least once, within the last 3 months prior to the Baseline Visit, or participants with an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours or ≥ 50% within 7 days prior to the Baseline Visit.~Exclusion Criteria:~* Participants with simple liver cysts only.~* Any investigational drug or device within 6 weeks prior to the Baseline Visit.~* Any magnetic resonance imaging (MRI) contrast media within 6 weeks prior to Baseline Visit or scheduled to receive any contrast medium before the last study visit.~* Participants with severe hepatic impairment (according to Child-Pugh score C).~* Participants scheduled for surgery before last study visit.~* Participants with encephalopathy / neurodegenerative or acute neurological disorders.~* Participants with hemochromatosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mangoral (Type: EXPERIMENTAL): All participants will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate \[MnCl2 4H2O\]).

Based on this trial design, predict the completion outcome and termination type (if applicable).